J&J’s Top 10 List: Updates From Pharma Business Review
J&J presented a far-reaching overview of its pharmaceutical portfolio and pipeline at an analyst day May 20, including plans to break into immuno-oncology, a strategy to develop a pan-genotypic HCV regimen and several filing timelines for new drugs.
You may also be interested in...
As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.
The number of new drugs that launched in 2021 was on par with recent high trends, but launch trajectories generally underwhelmed commercially – except for COVID-19 vaccines.